CSCIF
COSCIENS Biopharma Inc.
Price Chart
Latest Quote
$2.30
+0.15 (+6.98%)
Current Price
| Previous Close | $2.15 |
| Open | $2.30 |
| Day High | $2.30 |
| Day Low | $2.30 |
| Volume | 400 |
Stock Information
| Shares Outstanding | 3.18M |
| Total Debt | $2.02M |
| Cash Equivalents | $5.00M |
| Revenue | $8.00M |
| Net Income | $-7.87M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $7.32M |
| EPS (TTM) | $-2.48 |
| Exchange | OQB |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $3.86M |
| Sales | $8.00M |
| Income | $-7.87M |
| Book/sh | $4.81 |
| Cash/sh | $1.57 |
| Employees | 28 |
Financial Ratios
| Quick Ratio | 4.15 |
| Current Ratio | 5.57 |
| Debt/Eq | 13.21 |
Returns & Margins
| ROA | -21.29% |
| ROE | -61.79% |
| Gross Margin | 37.44% |
| Operating Margin | -38.66% |
| Profit Margin | 50.68% |
Ownership
| Insider Ownership | 0.55% |
| Institutional Ownership | 8.08% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/S | 0.92 |
| P/B | 0.48 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $1.99 |
| SMA50 | $1.97 |
| SMA200 | $2.08 |
| RSI | 57.04 |
| ATR | 0.1914 |
| Shares Float | 3.17M |
| Short Float | 0.26% |
| Short Ratio | 0.55 |
| Volatility | 1.93 |
| Rel Volume | 0.60 |
Performance History
| Week | +13.30% |
| Month | +22.99% |
| Quarter | +116.98% |
| 6 Months | +10.58% |
| YTD | +11.65% |
| Year | -37.50% |
| 3 Years | -79.90% |
| 5 Years | -97.75% |
| 10 Years | -99.36% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $2.30 | 2,500 |
| 2026-06-16 | $2.15 | 2,500 |
| 2026-06-15 | $2.16 | 13,200 |
| 2026-06-12 | $2.05 | 2,700 |
| 2026-06-11 | $2.03 | 0 |
| 2026-06-10 | $2.03 | 800 |
| 2026-06-09 | $1.97 | 1,600 |
| 2026-06-08 | $2.04 | 11,500 |
| 2026-06-05 | $1.82 | 300 |
| 2026-06-04 | $2.00 | 4,200 |
| 2026-06-03 | $2.00 | 15,300 |
| 2026-06-02 | $1.85 | 7,600 |
| 2026-06-01 | $2.10 | 500 |
| 2026-05-29 | $2.00 | 4,400 |
| 2026-05-28 | $2.10 | 3,500 |
| 2026-05-27 | $1.96 | 5,700 |
| 2026-05-26 | $1.85 | 2,700 |
| 2026-05-22 | $1.87 | 1,100 |
| 2026-05-21 | $1.76 | 1,400 |
| 2026-05-20 | $1.84 | 1,900 |
| 2026-05-19 | $1.87 | 0 |
| 2026-05-18 | $1.87 | 0 |
About COSCIENS Biopharma Inc.
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a functional ingredient that supports overall health and wellness; oat powder and peptides; oat oil which is extracted from whole oat kernels by a gentle process that retains all the important biologically active components; and avenanthramides, a natural-based ingredients used to inflammation-based diseases for the cosmeceutical and pharmaceutical industries. It also provides Macrilen/Ghryvelin (macimorelin), an orally active peptidomimetic small molecule that stimulates the secretion of growth hormone from the pituitary gland. The company sells its products through its distribution network. It has license agreements with Pharmanovia, Davimed GmbH, and NK MEDITECH Ltd, as well as Agriculture Canada, Canadian Government, and University of Alberta. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.
đ° Latest News
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $4,858,000 | $4,205,000 | $6,016,000 | $5,276,544 |
| Cost Of Revenue | $4,858,000 | $4,205,000 | $6,016,000 | $5,276,544 |
| Total Revenue | $9,587,000 | $7,143,000 | $14,572,000 | $13,486,321 |
| Operating Revenue | $9,587,000 | $7,143,000 | $14,572,000 | $13,486,321 |
| Expenses | ||||
| Interest Expense | $129,000 | $136,000 | $143,000 | $119,128 |
| Total Expenses | $23,610,000 | $11,772,000 | $10,252,000 | $10,896,093 |
| Other Income Expense | $-1,514,000 | $336,000 | $206,000 | $158,649 |
| Other Non Operating Income Expenses | $98,000 | $360,000 | $-5,000 | $214,212 |
| Net Non Operating Interest Income Expense | $312,000 | $-77,000 | $2,000 | $-162,265 |
| Interest Expense Non Operating | $129,000 | $136,000 | $143,000 | $119,128 |
| Operating Expense | $18,752,000 | $7,567,000 | $4,236,000 | $5,619,549 |
| General And Administrative Expense | $10,448,000 | $5,527,000 | $2,865,000 | $2,540,879 |
| Total Other Finance Cost | - | $41,459 | $40,525 | $43,137 |
| Selling And Marketing Expense | - | $30,517 | $21,779 | $36,955 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-15,309,000 | $-3,485,000 | $3,448,000 | $2,639,531 |
| Net Interest Income | $312,000 | $-77,000 | $2,000 | $-162,265 |
| Interest Income | $441,000 | $59,000 | $145,000 | - |
| Normalized Income | $-13,938,800 | $-3,465,860 | $3,287,327 | $2,680,369 |
| Net Income From Continuing And Discontinued Operation | $-15,309,000 | $-3,485,000 | $3,448,000 | $2,639,531 |
| Total Operating Income As Reported | $-18,280,000 | $-4,629,000 | $4,320,000 | $2,427,963 |
| Net Income Common Stockholders | $-15,309,000 | $-3,485,000 | $3,448,000 | $2,639,531 |
| Net Income | $-15,309,000 | $-3,485,000 | $3,448,000 | $2,639,531 |
| Net Income Including Noncontrolling Interests | $-15,309,000 | $-3,485,000 | $3,448,000 | $2,639,531 |
| Net Income Continuous Operations | $-15,309,000 | $-3,485,000 | $3,448,000 | $2,639,531 |
| Pretax Income | $-15,225,000 | $-4,370,000 | $4,528,000 | $2,586,612 |
| Special Income Charges | $-4,257,000 | $0 | $0 | $3,922 |
| Interest Income Non Operating | $441,000 | $59,000 | $145,000 | - |
| Operating Income | $-14,023,000 | $-4,629,000 | $4,320,000 | $2,590,228 |
| Gross Profit | $4,729,000 | $2,938,000 | $8,556,000 | $8,209,777 |
| Per Share | ||||
| Diluted EPS | $-5.93 | $-1.89 | $1.86 | $1.33 |
| Basic EPS | $-5.93 | $-1.89 | $1.87 | $1.33 |
| Other | ||||
| Tax Effect Of Unusual Items | $-241,800 | $-4,860 | $50,327 | $-14,724 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-11,877,000 | $-2,767,000 | $5,928,000 | $4,236,376 |
| Total Unusual Items | $-1,612,000 | $-24,000 | $211,000 | $-55,562 |
| Total Unusual Items Excluding Goodwill | $-1,612,000 | $-24,000 | $211,000 | $-55,562 |
| Reconciled Depreciation | $1,607,000 | $1,443,000 | $1,468,000 | $1,475,073 |
| EBITDA (Bullshit earnings) | $-13,489,000 | $-2,791,000 | $6,139,000 | $4,180,814 |
| EBIT | $-15,096,000 | $-4,234,000 | $4,671,000 | $2,705,740 |
| Diluted Average Shares | $2,581,308 | $1,847,233 | $1,854,537 | $1,854,740 |
| Basic Average Shares | $2,581,308 | $1,847,233 | $1,839,896 | $1,833,101 |
| Diluted NI Availto Com Stockholders | $-15,309,000 | $-3,485,000 | $3,448,000 | $2,639,531 |
| Tax Provision | $84,000 | $-885,000 | $1,080,000 | $-52,919 |
| Impairment Of Capital Assets | $4,257,000 | $0 | $0 | - |
| Gain On Sale Of Security | $2,645,000 | $-24,000 | $211,000 | $-59,484 |
| Research And Development | $8,304,000 | $2,040,000 | $1,371,000 | $3,041,715 |
| Selling General And Administration | $10,448,000 | $5,527,000 | $2,865,000 | $2,577,835 |
| Other Gand A | $6,637,000 | $3,507,000 | $1,564,000 | $2,540,879 |
| Insurance And Claims | $732,000 | $170,000 | $161,000 | - |
| Salaries And Wages | $3,079,000 | $1,850,000 | $1,140,000 | - |
| Gain On Sale Of Ppe | - | - | $0 | $3,922 |
| Restructuring And Mergern Acquisition | - | - | - | $0 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $13,161,000 | $21,028,000 | $23,781,684 | $21,728,680 |
| Total Assets | $35,070,000 | $23,745,000 | $27,803,176 | $24,353,365 |
| Total Non Current Assets | $11,089,000 | $12,478,000 | $12,633,504 | $14,622,784 |
| Other Non Current Assets | $123,000 | $8,000 | - | - |
| Non Current Deferred Assets | $0 | $75,000 | $0 | $221,839 |
| Non Current Deferred Taxes Assets | $0 | $75,000 | $0 | $221,839 |
| Goodwill And Other Intangible Assets | $0 | $7,000 | $9,275 | $12,197 |
| Current Assets | $23,981,000 | $11,267,000 | $15,169,672 | $9,730,581 |
| Other Current Assets | $210,000 | $112,000 | - | - |
| Prepaid Assets | $2,216,000 | $178,000 | $99,567 | $127,778 |
| Inventory | $2,691,000 | $4,009,000 | $2,768,229 | $1,822,783 |
| Receivables | $2,471,000 | $290,000 | $2,125,780 | $1,677,379 |
| Taxes Receivable | $114,000 | $0 | - | - |
| Accounts Receivable | $2,357,000 | $290,000 | $2,078,028 | $1,641,419 |
| Cash Cash Equivalents And Short Term Investments | $16,393,000 | $6,678,000 | $10,176,096 | $6,102,641 |
| Cash And Cash Equivalents | $16,393,000 | $6,678,000 | $10,176,096 | $6,102,641 |
| Cash Financial | $16,393,000 | $6,678,000 | $10,176,096 | - |
| Non Current Prepaid Assets | - | $56,060 | $56,701 | $62,383 |
| Non Current Accounts Receivable | - | $743,000 | $629,896 | $601,268 |
| Other Intangible Assets | - | $7,000 | $9,275 | $12,197 |
| Other Receivables | - | $163,397 | $47,751 | $35,960 |
| Debt | ||||
| Total Debt | $2,310,000 | $1,698,000 | $1,929,735 | $2,077,549 |
| Long Term Debt And Capital Lease Obligation | $2,039,000 | $1,399,000 | $1,656,776 | $1,850,059 |
| Current Debt And Capital Lease Obligation | $271,000 | $299,000 | $272,959 | $227,491 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $21,909,000 | $2,710,000 | $4,012,218 | $2,612,488 |
| Total Non Current Liabilities Net Minority Interest | $14,687,000 | $1,399,000 | $2,464,298 | $1,850,059 |
| Non Current Deferred Liabilities | $914,000 | $0 | $807,521 | $0 |
| Current Liabilities | $7,222,000 | $1,311,000 | $1,547,920 | $762,429 |
| Other Current Liabilities | $1,563,000 | - | - | - |
| Current Deferred Liabilities | $168,000 | $0 | - | - |
| Payables And Accrued Expenses | $4,228,000 | $882,000 | $1,274,961 | $534,938 |
| Payables | $2,537,000 | $281,000 | - | - |
| Total Tax Payable | $130,000 | $0 | - | - |
| Income Tax Payable | $105,000 | $0 | - | - |
| Accounts Payable | $2,407,000 | $281,000 | - | - |
| Non Current Deferred Taxes Liabilities | - | $0 | $807,521 | $0 |
| Equity | ||||
| Common Stock Equity | $13,161,000 | $21,035,000 | $23,790,959 | $21,740,877 |
| Total Equity Gross Minority Interest | $13,161,000 | $21,035,000 | $23,790,959 | $21,740,877 |
| Stockholders Equity | $13,161,000 | $21,035,000 | $23,790,959 | $21,740,877 |
| Gains Losses Not Affecting Retained Earnings | $-1,483,000 | $-712,000 | - | - |
| Other Equity Adjustments | $-1,483,000 | $-712,000 | - | - |
| Retained Earnings | $-12,110,000 | $4,356,000 | $8,016,549 | $5,083,812 |
| Other | ||||
| Ordinary Shares Number | $3,140,621 | $1,847,718 | $1,846,302 | $1,833,385 |
| Share Issued | $3,140,621 | $1,847,718 | $1,846,302 | $1,833,385 |
| Tangible Book Value | $13,161,000 | $21,028,000 | $23,781,684 | $21,728,680 |
| Invested Capital | $13,161,000 | $21,035,000 | $23,790,959 | $21,740,877 |
| Working Capital | $16,759,000 | $9,956,000 | $13,621,752 | $8,968,152 |
| Capital Lease Obligations | $2,310,000 | $1,698,000 | $1,929,735 | $2,077,549 |
| Total Capitalization | $13,161,000 | $21,035,000 | $23,790,959 | $21,740,877 |
| Additional Paid In Capital | $4,268,000 | $3,874,000 | $3,473,625 | $3,671,072 |
| Capital Stock | $22,486,000 | $13,517,000 | $12,300,785 | $12,985,993 |
| Common Stock | $22,486,000 | $13,517,000 | $12,300,785 | $12,985,993 |
| Employee Benefits | $11,734,000 | $0 | - | - |
| Non Current Deferred Revenue | $914,000 | $0 | - | - |
| Long Term Capital Lease Obligation | $2,039,000 | $1,399,000 | $1,656,776 | $1,850,059 |
| Current Deferred Revenue | $120,000 | $0 | - | - |
| Current Capital Lease Obligation | $271,000 | $299,000 | $272,959 | $227,491 |
| Pensionand Other Post Retirement Benefit Plans Current | $607,000 | $130,000 | - | - |
| Current Provisions | $385,000 | - | - | - |
| Current Accrued Expenses | $1,691,000 | $601,000 | - | - |
| Net PPE | $10,966,000 | $11,645,000 | $11,937,633 | $13,725,098 |
| Accumulated Depreciation | $-9,133,000 | $-9,804,000 | $-8,572,437 | $-7,631,133 |
| Gross PPE | $20,099,000 | $21,449,000 | $20,510,070 | $21,356,230 |
| Leases | $5,644,000 | $6,680,000 | $6,433,013 | $6,842,598 |
| Other Properties | $10,527,000 | $11,258,000 | $10,671,597 | $11,182,237 |
| Machinery Furniture Equipment | $376,000 | $717,000 | $679,344 | $640,727 |
| Buildings And Improvements | $3,552,000 | $2,794,000 | $2,726,116 | $2,690,668 |
| Properties | $0 | $0 | $0 | $0 |
| Other Inventories | $1,954,000 | $3,131,000 | $2,131,096 | $1,392,184 |
| Finished Goods | $299,000 | $544,000 | $268,846 | $227,019 |
| Work In Process | $1,655,000 | $2,587,000 | $1,862,249 | $1,165,165 |
| Raw Materials | $737,000 | $878,000 | $637,133 | $430,599 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-15,729,000 | $-3,304,000 | $4,925,000 | $2,197,281 |
| Operating Activities | ||||
| Operating Cash Flow | $-14,568,000 | $-2,582,000 | $5,229,000 | $2,753,274 |
| Cash Flow From Continuing Operating Activities | $-14,568,000 | $-2,582,000 | $5,229,000 | $2,753,274 |
| Operating Gains Losses | $-2,302,000 | - | - | $-3,922 |
| Investing Activities | ||||
| Capital Expenditure | $-1,161,000 | $-722,000 | $-304,000 | $-555,994 |
| Investing Cash Flow | $25,083,000 | $-730,000 | $-304,000 | $-620,149 |
| Cash Flow From Continuing Investing Activities | $25,083,000 | $-730,000 | $-304,000 | $-620,149 |
| Net Other Investing Changes | $207,000 | $-8,000 | $-35,186 | $-68,077 |
| Financing Activities | ||||
| Financing Cash Flow | $-588,000 | $-357,000 | $-267,000 | $-241,421 |
| Cash Flow From Continuing Financing Activities | $-588,000 | $-357,000 | $-267,000 | $-241,421 |
| Net Other Financing Charges | - | $-7,538 | - | - |
| Other | ||||
| Repayment Of Debt | $-421,000 | $-370,000 | $-330,000 | $-262,382 |
| End Cash Position | $16,393,000 | $6,678,000 | $10,190,000 | $6,102,641 |
| Beginning Cash Position | $6,678,000 | $10,190,000 | $6,157,000 | $4,210,937 |
| Effect Of Exchange Rate Changes | $-212,000 | $157,000 | $-625,000 | - |
| Changes In Cash | $9,927,000 | $-3,669,000 | $4,658,000 | $1,891,704 |
| Proceeds From Stock Option Exercised | $-167,000 | $13,000 | $63,000 | $20,960 |
| Net Issuance Payments Of Debt | $-421,000 | $-370,000 | $-330,000 | $-262,382 |
| Net Long Term Debt Issuance | $-421,000 | $-370,000 | $-330,000 | $-262,382 |
| Long Term Debt Payments | $-421,000 | $-370,000 | $-330,000 | $-262,382 |
| Net Business Purchase And Sale | $26,037,000 | $0 | $0 | - |
| Sale Of Business | $26,037,000 | $0 | $0 | - |
| Net PPE Purchase And Sale | $-1,161,000 | $-722,000 | $-304,000 | $-552,072 |
| Purchase Of PPE | $-1,161,000 | $-722,000 | $-304,000 | $-555,994 |
| Change In Working Capital | $-2,514,000 | $58,000 | $-936,000 | $-1,158,728 |
| Other Non Cash Items | $-850,000 | $95,000 | $100,000 | $119,128 |
| Stock Based Compensation | $464,000 | $192,000 | $69,000 | $14,044 |
| Asset Impairment Charge | $4,257,000 | $0 | $0 | - |
| Deferred Tax | $79,000 | $-885,000 | $1,080,000 | $-221,839 |
| Deferred Income Tax | $79,000 | $-885,000 | $1,080,000 | $-221,839 |
| Depreciation Amortization Depletion | $1,607,000 | $1,443,000 | $1,468,000 | $1,475,073 |
| Depreciation And Amortization | $1,607,000 | $1,443,000 | $1,468,000 | $1,475,073 |
| Amortization Cash Flow | $162,000 | $2,234 | - | - |
| Amortization Of Intangibles | $162,000 | $2,234 | - | - |
| Depreciation | $1,445,000 | $1,465,259 | - | - |
| Pension And Employee Benefit Expense | $288,000 | $0 | $0 | - |
| Gain Loss On Investment Securities | $-2,590,000 | - | - | - |
| Net Income From Continuing Operations | $-15,309,000 | $-3,485,000 | $3,448,000 | $2,639,531 |
| Interest Paid Cfo | - | $-96,585 | $-95,761 | $-110,014 |
| Change In Payables And Accrued Expense | - | $-430,748 | $807,599 | $-234,322 |
| Change In Prepaid Assets | - | $-130,011 | $22,378 | $87,092 |
| Change In Inventory | - | $-1,169,868 | $-1,055,817 | $-873,716 |
| Change In Receivables | - | $1,787,837 | $-615,003 | $-137,781 |
| Changes In Account Receivables | - | $1,999,853 | $-535,999 | $-57,347 |
| Sale Of PPE | - | - | $0 | $3,922 |
| Gain Loss On Sale Of PPE | - | - | $0 | $-3,922 |
Fetched: 2026-02-02